Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC001 + Sintilimab + XELOX in First-Line Advanced Gastric Cancer
NCT06773312Phase 1Recruiting
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BC001 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Sichuan Luzhou Buchang Biopharmaceutical. Primary endpoints: Adverse events at 2 years, Maximum Tolerated Dose at 21 days and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
BC001
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06773312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773312.